Buthionine sulfoximine and chemoresistance in cancer treatments: a systematic review with meta-analysis of preclinical studies

References

• Anderson, C. P., and C. P. P. Reynolds. 2002. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant. 30 (3):135–40. doi:10.1038/sj.bmt.1703605.
   PubMed Web of Science ®Google Scholar
• Anderson, C. P., J. M. Tsai, W. E. Meek, R. M. Liu, Y. Tang, H. J. Forman, and C. P. Reynolds. 1999. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp. Cell Res. 246 (1):183–92. doi:10.1006/excr.1998.4303.
   PubMed Web of Science ®Google Scholar
• Anderstam, B., and M. Harms-Ringdahl. 1988. Increased antineoplastic activity of combined hyperthermic and bleomycin treatments in an adenocarcinoma after glutathione depletion in vivo. Int. J. Hyperthermia. 4 (3):297–306. doi:10.3109/02656738809051105.
   PubMed Web of Science ®Google Scholar
• Araújo, E. J. F., G. A. L. Oliveira, L. Q. Sousa, V. S. Bolzani, A. J. Cavalheiro, A. R. Tomé, A. P. Peron, A. G. Santos, A. M. G. L. Citó, C. Pessoa, et al. 2015. Counteracting effects on free radicals and histological alterations induced by a fraction with casearins. An. Acad. Bras. Ciênc. 87 (3):1791–807. doi:10.1590/0001-3765201520150149.
   PubMed Web of Science ®Google Scholar
• Arrick, B. A., C. F. Nathan, and Z. A. Cohn. 1983. Inhibition of glutathione synthesis augments lysis of murine tumor cells by sulfhydryl-reactive antineoplastics. J. Clin. Invest. 71 (2):258–67. doi:10.1172/jci110766.
   PubMed Web of Science ®Google Scholar
• Asantewaa, G., and I. S. Harris. 2021. Glutathione and its precursors in cancer. Curr. Opin. Biotechnol. 68:292–99. doi:10.1016/j.copbio.2021.03.001.
   PubMed Web of Science ®Google Scholar
• Bailey, H. H., R. T. Mulcahy, K. D. Tutsch, R. Z. Arzoomanian, D. Alberti, M. B. Tombes, G. Wilding, M. Pomplun, and D. R. Spriggs. 1994. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione. J. Clin. Oncol. 12 (1):194–205. doi:10.1200/JCO.1994.12.1.194.
   PubMed Web of Science ®Google Scholar
• Bailey, H. H., G. Ripple, K. D. Tutsch, R. Z. Arzoomanian, D. Alberti, C. Feierabend, D. Mahvi, J. Schink, M. Pomplun, R. T. Mulcahy, et al. 1997. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J. Natl. Cancer Inst. 89:1789–96. doi:10.1093/jnci/89.23.1789.
   PubMed Web of Science ®Google Scholar
• Bansal, A., D. J. Sanchez, V. Nimgaonkar, D. Sanchez, R. Riscal, N. Skuli, and M. C. Simon. 2019. Gamma-glutamyltransferase 1 promotes clear cell renal cell carcinoma initiation and progression. Mol. Cancer Res. 17 (9):1881–92. doi:10.1158/1541-7786.MCR-18-1204.
   PubMed Web of Science ®Google Scholar
• Bergamini, F. R. G., M. A. Ferreira, R. E. F. Paiva, A. F. Gomes, F. C. Gozzo, A. L. B. Formiga, F. C. A. Corbi, I. O. Mazali, D. A. Alves, M. Lancellotti, et al. 2012. A binuclear silver complex with l-buthionine sulfoximine: Synthesis, spectroscopic characterization, DFT studies and antibacterial assays. RSC Adv. 2 (27):10372–79. doi:10.1039/C2RA21433D.
   Web of Science ®Google Scholar
• Brasil. 2021. Diretrizes metodológicas: Elaboração de revisão sistemática e meta-análise de ensaios clínicos randomizados. Brasília: Ministerio da Saúde. http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_elaboracao_revisao_sistematica_meta-analise.pdf
   Google Scholar
• Calvin, H. I., S. A. Patel, J. P. Zhang, M. Y. Li, and S. C. Fu. 1992. Progressive modifications of mouse lens crystallins in cataracts induced by buthionine sulfoximine. Exp. Eye Res. 54:611–19. doi:10.1016/0014-4835(92)90140-n.
   PubMed Web of Science ®Google Scholar
• Caramés, M., A. Alonso-Varona, I. García-Alonso, and T. Palomares. 2010. Glutathione modulators reverse the pro-tumour effect of growth factors enhancing WiDr cell response to chemotherapeutic agents. Anticancer Res. 30 (4):1223–31.
   PubMed Web of Science ®Google Scholar
• Chen, C. L., C. W. Chi, and T. Y. Liu. 2000. Enhanced hydroxychavicol-induced cytotoxic effects in glutathione-depleted HepG2 cells. Cancer Lett. 155:29–35. doi:10.1016/s0304-3835(00)00404-3.
   PubMed Web of Science ®Google Scholar
• Cilurzo, F., M. C. Cristiano, M. Da Pian, E. Cianflone, L. Quintieri, D. Paolino, and G. Pasut. 2019. Overcoming cancer cell drug resistance by a folic acid targeted polymeric conjugate of buthionine sulfoximine. Anticancer. Agents Med. Chem. 19:1513–22. doi:10.2174/1871520619666190626114641.
   PubMed Web of Science ®Google Scholar
• Coshan-Gauthier, R. K., and D. L. Kirkpatrick. 1989. Attempted modulation of disulfide antitumor activity in Balb/c mice through glutathione depletion. Exp. Cell Biol. 57:273–80. doi:10.1159/000163537.
   PubMedGoogle Scholar
• Cruz, A., P. Mota, C. Ramos, R. F. Pires, C. Mendes, J. P. Silva, S. C. Nunes, V. D. B. Bonifácio, and J. Serpa. 2020. Polyurea dendrimer folate-targeted nanodelivery of l-buthionine sulfoximine as a tool to tackle ovarian cancer chemoresistance. Antioxidants 9 (2):133. doi:10.3390/antiox9020133.
   Web of Science ®Google Scholar
• Daga, M., C. Ullio, M. Argenziano, C. Dianzani, R. Cavalli, F. Trotta, C. Ferretti, G. P. Zara, C. L. Gigliotti, E. S. Ciamporcero, et al. 2016. GSH-targeted nanosponges increase doxorubicin-induced toxicity “in vitro” and “in vivo” in cancer cells with high antioxidant defenses. Free Radic. Biol. Med. 97:24–37. doi:10.1016/j.freeradbiomed.2016.05.009.
   PubMed Web of Science ®Google Scholar
• Day, C. P., G. Merlino, and T. Van Dyke. 2015. Preclinical mouse cancer models: A maze of opportunities and challenges. Cell 163 (1):39–53. doi:10.1016/j.cell.2015.08.068.
   PubMed Web of Science ®Google Scholar
• Deeks, J. J., J. P. Higgins, and D. G. Altman. 2022. Chapter 10: Analysing data and undertaking meta-analyses. In Cochrane handbook for systematic reviews of interventions version 6.3. Cochrane. Updated February 2022. Available from https://training.cochrane.org/handbook/current.
   Google Scholar
• DerSimonian, R., and N. Laird. 1986. Meta-analysis in clinical trials. Control Clin. Trials 7 (3):177–88. doi:10.1016/0197-2456(86)90046-2.
   PubMedGoogle Scholar
• Domcke, S., R. Sinha, D. A. Levine, C. Sander, and N. Schultz. 2013. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4 (1):2126. doi:10.1038/ncomms3126.
   PubMedGoogle Scholar
• Dong, Z., L. Feng, Y. Chao, Y. Hao, M. Chen, F. Gong, X. Han, R. Zhang, L. Cheng, and Z. Liu. 2019. Amplification of tumor oxidative stresses with liposomal fenton catalyst and glutathione inhibitor for enhanced cancer chemotherapy and radiotherapy. Nano Lett. 19 (2):805–15. doi:10.1021/acs.nanolett.8b03905.
   PubMed Web of Science ®Google Scholar
• Dorr, R. T., J. D. Liddil, and M. J. Soble. 1986. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells. Invest. New Drugs 4 (4):305–13. doi:10.1007/BF00173503.
   PubMed Web of Science ®Google Scholar
• Edis, Z., J. Wang, M. K. Waqas, M. Ijaz, and M. Ijaz. 2021. Nanocarriers-mediated drug delivery systems for anticancer agents: An overview and perspectives. Int. J. Nanomed 16:1313–30. doi:10.2147/IJN.S289443.
   PubMed Web of Science ®Google Scholar
• Faundez, M., L. Pino, P. Letelier, C. Ortiz, R. López, C. Seguel, J. Ferreira, M. Pavani, A. Morello, and J. D. Maya. 2005. Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi. Antimicrob. Agents Chemother. 49 (1):126–30. doi:10.1128/AAC.49.1.126-130.2005.
   PubMed Web of Science ®Google Scholar
• Ferreira, P. M. P., J. R. O. Ferreira, R. W. R. Sousa, D. P. Bezerra, and G. C. G. Militão. 2021. Aminoquinolines as translational models for drug repurposing: Anticancer adjuvant properties and toxicokinetic-related features. J. Oncol. 2021:1–18. doi:10.1155/2021/3569349.
   Web of Science ®Google Scholar
• Ferreira, P. M. P., and C. Pessoa. 2017. Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: New evidences and old challenges. Braz. J. Pharm. Sci. 53 (2):16076. doi:10.1590/s2175-97902017000216076.
   Web of Science ®Google Scholar
• Ferreira, P. M. P., L. A. R. L. Rodrigues, L. P. A. Carnib, P. V. L. Sousa, L. M. N. Lugo, N. M. F. Nunes, J. N. Silva, L. S. Araújo, and K. M. G. Frota. 2018. Cruciferous vegetables as antioxidative, chemopreventive and antineoplasic functional foods: Preclinical and clinical evidences of sulforaphane against prostate cancers. Curr. Pharm. Des. 24 (40):4779–93. doi:10.2174/1381612825666190116124233.
   PubMed Web of Science ®Google Scholar
• Fischer, M. L., and G. S. Rodrigues. 2018. Planejamento e divulgação da pesquisa com animais como parâmetro de integridade. Rev. Bioét 26 (4):543–55. doi:10.1590/1983-80422018264273.
   Google Scholar
• Forman, H. J., H. Zhang, and A. Rinna. 2009. Glutathione: Overview of its protective roles, measurement, and biosynthesis. Mol. Aspects Med. 30:1–12. doi:10.1016/j.mam.2008.08.006.
   PubMed Web of Science ®Google Scholar
• Gana, C. C., K. M. Hanssen, D. M. T. Yu, C. L. Flemming, M. S. Wheatley, G. Conseil, S. P. C. Cole, M. D. Norris, M. Haber, and J. I. Fletcher. 2019. MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. Biochem. Pharmacol. 168:237–48. doi:10.1016/j.bcp.2019.07.009.
   PubMed Web of Science ®Google Scholar
• Gartenhaus, R. B., S. N. Prachand, M. Paniaqua, Y. Li, and L. I. Gordon. 2002. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: Enhancement of apoptosis by manipulation of cellular redox state. Clin. Cancer Res. 8 (2):566–72.
   PubMed Web of Science ®Google Scholar
• Gong, M. Q., C. Wu, X. Y. He, J. Y. Zong, J. L. Wu, R. X. Zhuo, and S. X. Cheng. 2017. Tumor targeting synergistic drug delivery by self-assembled hybrid nanovesicles to overcome drug resistance. Pharm. Res. 34 (1):148–60. doi:10.1007/s11095-016-2051-9.
   PubMed Web of Science ®Google Scholar
• Gorrini, C., I. S. Harris, and T. W. Mak. 2013. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug. Discov. 12 (12):931–47. doi:10.1038/nrd4002.
   PubMed Web of Science ®Google Scholar
• Goto, H., M. Yanagimachi, R. Kajiwara, F. Kuroki, and S. Yokota. 2007. Lack of mitochondrial depolarization by oxidative stress is associated with resistance to buthionine sulfoximine in acute lymphoblastic leukemia cells. Leuk. Res. 31:1293–301. doi:10.1016/j.leukres.2007.01.003.
   PubMed Web of Science ®Google Scholar
• Griffith, O. W. 1982. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J. Biol. Chem. 257 (22):13704–12. doi:10.1016/S0021-9258(18)33504-X.
   PubMed Web of Science ®Google Scholar
• Griffith, O. W., and A. Meister. 1979. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254 (16):7558–60. doi:10.1016/S0021-9258(18)35980-5.
   PubMed Web of Science ®Google Scholar
• Hadzic, T., N. Aykin-Burns, Y. Zhu, M. C. Coleman, K. Leick, G. M. Jacobson, and D. R. Spitz. 2010. Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress. Free Radic. Biol. Med. 48:1024–33. doi:10.1016/j.freeradbiomed.2010.01.018.
   PubMed Web of Science ®Google Scholar
• Han, Y. H., S. Z. Kim, S. H. Kim, and W. H. Park. 2008a. Enhancement of arsenic trioxide-induced apoptosis in HeLa cells by diethyldithiocarbamate or buthionine sulfoximine. Int. J. Oncol. 33:205–13. doi:10.3892/ijo.33.1.205.
   PubMed Web of Science ®Google Scholar
• Han, Y. H., S. Z. Kim, S. H. Kim, and W. H. Park. 2008b. Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine. Mol. Cells 26 (2):158–64.
   PubMed Web of Science ®Google Scholar
• Hernández-Breijo, B., J. Monserrat, S. Ramírez-Rubio, E. P. Cuevas, D. Vara, I. Díaz-Laviada, M. D. Fernández-Moreno, I. D. Román, J. P. Gisbet, and L. G. Guijarro. 2011. Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma. World J.Gastroenterol. 17(34):3899–911. doi:10.3748/wjg.v17.i34.3899.
   PubMed Web of Science ®Google Scholar
• Higgins, J. P., T. Li, and J. J. Deeks. 2021. Chapter 6: Choosing effect measures and computing estimates of effect. In Cochrane Handbook for Systematic Reviews of Interventions Version 6.2, ed. J. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M. Page, and V. Welch. Cochrane. updated February 2021. Available from https://training.cochrane.org/handbook/current.
   Google Scholar
• Hooijmans, C. R., M. M. Rovers, R. B. Vries, M. Leenaars, M. Ritskes-Hoitinga, and M. W. Langendam. 2014. SYRCLE’s risk of bias tool for animal studies. BMC Med. Res. Meth 14 (1):43. doi:10.1186/1471-2288-14-43.
   PubMed Web of Science ®Google Scholar
• Hounsell, C., and Y. Fan. 2021. The duality of caspases in cancer, as told through the fly. Int. J. Mol. Sci. 22:8927. doi:10.3390/ijms22168927.
   PubMedGoogle Scholar
• Huber, P. C., W. P. Almeida, and A. Fátima. 2008. Glutationa e enzimas relacionadas: papel biológico e importância em processos patológicos. Quím. Nova 31 (5):1170–79. doi:10.1590/S0100-40422008000500046.
   Google Scholar
• Jafari, M., V. Sriram, G. Premnauth, E. Merino, and J. Y. Lee. 2022. Modified peroxamide-based reactive oxygen species (ROS)-responsive doxorubicin prodrugs. Bioorg. Chem. 127:105990. doi:10.1016/j.bioorg.2022.105990.
   PubMed Web of Science ®Google Scholar
• Jagust, P., S. Alcalá, B. Sainz Jr, C. Heeschen, and P. Sancho. 2020. Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells. World J. Stem. Cells 12 (11):1410–28. doi:10.4252/wjsc.v12.i11.1410.
   PubMed Web of Science ®Google Scholar
• Jiang, G., S. Zhang, A. Yazdanparast, M. Li, A. V. Pawar, Y. Liu, S. M. Inavolu, and L. Cheng. 2016. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. Bmc Genomics. 17 (S7):525. doi:10.1186/s12864-016-2911-z.
   PubMedGoogle Scholar
• Kapoor, P., M. Sachdev, and R. Madhubala. 2000. Inhibition of glutathione synthesis as a chemotherapeutic strategy for leishmaniasis. Trop. Med. Int. Health 5 (6):438–42. doi:10.1046/j.1365-3156.2000.00565.x.
   PubMed Web of Science ®Google Scholar
• Kermanizadeh, A., I. Gosens, L. MacCalman, H. Johnston, P. H. Danielsen, N. R. Jacobsen, A. G. Lenz, T. Fernandes, R. P. Schins, F. R. Cassee, et al. 2016. A multilaboratory toxicological assessment of a panel of 10 engineered nanomaterials to human Health—ENPRA project—the highlights, limitations, and current and future challenges. J. Toxicol. Environ. Health B 19 (1):1–28. doi:10.1080/10937404.2015.1126210.
   PubMed Web of Science ®Google Scholar
• Kiebala, M., J. Skalska, C. Casulo, P. S. Brookes, D. R. Peterson, S. P. Hilchey, Y. Dai, S. Grant, S. B. Maggirwar, and S. H. Bernstein. 2015. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: A novel synergistic therapeutic approach. Exp. Hematol. 43 (2):89–99. doi:10.1016/j.exphem.2014.10.004.
   PubMed Web of Science ®Google Scholar
• Kim, S. J., H. S. Kim, and Y. R. Seo. 2019. Understanding of ROS-inducing strategy in anticancer therapy. Oxid. Med. Cell Longev. 2019:5381692. doi:10.1155/2019/5381692.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick, D. L., and G. Powis. 2017. Clinically evaluated cancer drugs inhibiting redox signaling. Antioxid. Redox Signal. 26:262–73. doi:10.1089/ars.2016.6633.
   PubMed Web of Science ®Google Scholar
• Kitaeva, K. V., C. S. Rutland, A. A. Rizvanov, and V. V. Solovyeva. 2020. Cell culture based in vitro test systems for anticancer drug screening. Front Bioeng. Biotechnol. 8:322. doi:10.3389/fbioe.2020.00322.
   PubMed Web of Science ®Google Scholar
• Lai, G. M., J. A. Moscow, M. G. Alvarez, A. T. Fojo, and S. E. Bates. 1991. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int. J. Cancer 49 (5):688–95. doi:10.1002/ijc.2910490511.
   PubMed Web of Science ®Google Scholar
• Lee, M., A. Jo, S. Lee, J. B. Kim, Y. Chang, J. Y. Nam, H. Cho, Y. Y. Cho, E. J. Cho, J.-H. Lee, et al. 2017. 3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells. PLoS One. 12(3):e0174271. doi:10.1371/journal.pone.0174271.
   PubMed Web of Science ®Google Scholar
• Lee, H. M., D. H. Kim, H. L. Lee, B. Cha, D. H. Kang, and Y. I. Jeong. 2019. Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells. Arch. Pharm. Res. 42 (11):990–99. doi:10.1007/s12272-019-01179-0.
   PubMed Web of Science ®Google Scholar
• Lewandowicz, G. M., P. Britt, A. W. Elgie, C. J. Williamson, H. M. Coley, A. G. Hall, and J. M. Sargent. 2002. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. Gynecol. Oncol. 85:298–304. doi:10.1006/gyno.2002.6617.
   PubMed Web of Science ®Google Scholar
• Lewis, S. J., M. Gardner, J. Higgins, J. M. P. Holly, T. R. Gaunt, C. M. Perks, S. D. Turner, S. Rinaldi, S. Thomas, S. Harrison, et al. 2017. Developing the WCRF International/University of Bristol Methodology for identifying and carrying out systematic reviews of mechanisms of exposure–cancer associations. Cancer Epidemiol. Biomarkers Prev. 26(11):1667–75. doi:10.1158/1055-9965.EPI-17-0232.
   PubMed Web of Science ®Google Scholar
• Liaudat, A. C., L. P. Bohl, N. G. Tolosa de Talamoni, B. Maletto, M. C. Pistoresi-Palencia, and G. Picotto. 2014. Oxidative stress, cell cycle arrest and differentiation contribute toward the antiproliferative action of BSO and calcitriol on Caco-2 cells. Anticancer. Drugs 25 (7):810–18. doi:10.1097/CAD.0000000000000109.
   PubMed Web of Science ®Google Scholar
• Li, Q., H. Dong, G. Yang, Y. Song, Y. Mou, and Y. Ni. 2020. Mouse tumor-bearing models as preclinical study platforms for oral squamous cell carcinoma. Front Oncol. 10:212. doi:10.3389/fonc.2020.00212.
   PubMedGoogle Scholar
• Liebmann, J. E., S. M. Hahn, J. A. Cook, C. Lipschultz, J. B. Mitchell, and D. C. Kaufman. 1993. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res. 53 (9):2066–70.
   PubMed Web of Science ®Google Scholar
• Li, Y., R. W. Farmer, Y. Yang, and R. C. Martin. 2016. Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: A target of chemoresistence. BMC Cancer 16 (1):228. doi:10.1186/s12885-016-2252-y.
   PubMedGoogle Scholar
• Lippmann, J., K. Petri, S. Fulda, and J. Liese. 2020. Redox modulation and induction of ferroptosis as a new therapeutic strategy in hepatocellular carcinoma. Transl. Oncol. 13:100785. doi:10.1016/j.tranon.2020.100785.
   PubMed Web of Science ®Google Scholar
• Liu, B., Y. Bian, M. Yuan, Y. Zhu, S. Liu, H. Ding, S. Gai, P. Yang, Z. Cheng, and J. Lin. 2022. L-buthionine sulfoximine encapsulated hollow calcium peroxide as a chloroperoxidase nanocarrier for enhanced enzyme dynamic therapy. Biomaterals 289:121746. doi:10.1016/j.biomaterials.2022.121746.
   PubMed Web of Science ®Google Scholar
• Liu, M., W. Li, R. Xu, X. Jiang, and A. Liu. 2021. Hollow gold nanoparticles loaded with L-buthionine-sulfoximine as a novel nanomedicine for in vitro cancer cell therapy. null 2021:1–9. doi:10.1155/2021/3595470.
   Google Scholar
• Li, Q., X. Yin, W. Wang, M. Zhan, B. Zhao, Z. Hou, and J. Wang. 2016. The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine. Oncol. Lett. 11:474–80. doi:10.3892/ol.2015.3879.
   PubMed Web of Science ®Google Scholar
• Lorsch, J. R., F. S. Collins, and J. Lippincott-Schwartz. 2014. Cell biology. fixing problems with cell lines. Science 346 (6216):1452–53. doi:10.1126/science.1259110.
   PubMed Web of Science ®Google Scholar
• Luo, Y., P. Yan, X. Li, J. Hou, Y. Wang, and S. Zhou. 2021. pH-Sensitive polymeric vesicles for GOx/BSO delivery and synergetic starvation-ferroptosis therapy of tumor. Biomacromolecules 22 (10):4383–894. doi:10.1021/acs.biomac.1c00960.
   PubMed Web of Science ®Google Scholar
• Maeda, H., H. H. Ohizumi, T. Segawa, Y. Kakehi, O. Ogawa, and A. Kakizuka. 2004. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ. 11:737–46. doi:10.1038/sj.cdd.4401389.
   PubMed Web of Science ®Google Scholar
• Mårtensson, J., A. Jain, E. Stole, W. Frayer, P. A. Auld, and A. Meister. 1991. Inhibition of glutathione synthesis in the newborn rat: A model for endogenously produced oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 88:9360–64. doi:10.1073/pnas.88.20.9360.
   PubMed Web of Science ®Google Scholar
• Meister, A. 1991. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther. 51:155–94. doi:10.1016/0163-7258(91)90076-x.
   PubMed Web of Science ®Google Scholar
• Militão, G. C. G., I. N. F. Dantas, P. M. P. Ferreira, A. P. N. N. Alves, D. C. Chaves, F. J. Q. Monte, C. Pessoa, M. O. Moraes, and L. V. Costa-Lotufo. 2012. In vitro and in vivo anticancer properties of cucurbitacin isolated from Cayaponia racemosa. Pharm. Biol. 50 (12):1479–87. doi:10.3109/13880209.2012.684691.
   PubMed Web of Science ®Google Scholar
• Mustafa, E. H., H. T. Mahmoud, M. Y. Al-Hudhud, M. Y. Abdalla, I. M. Ahmad, S. R. Yasin, A. Z. Elkarmi, and L. H. Tahtamouni. 2015. 2-deoxy-D-glucose synergizes with doxorubicin or L-buthionine sulfoximine to reduce adhesion and migration of breast cancer cells. Asian Pac. J. Cancer Prev. 16 (8):3213–22. doi:10.7314/APJCP.2015.16.8.3213.
   PubMedGoogle Scholar
• Niepel, M., M. Hafner, M. Chung, and P. K. Sorger. 2017. Measuring cancer drug sensitivity and resistance in cultured cells. Curr. Protoc. Chem. Biol. 9 (2):55–74. doi:10.1002/cpch.21.
   PubMedGoogle Scholar
• Palomares, T., M. Caramés, I. García-Alonso, and A. Alonso-Varona. 2009. Glutathione modulation reverses the growth-promoting effect of growth factors, improving the 5-fluorouracil Antitumour response in WiDr colon cancer cells. Anticancer Res. 29 (10):3957–65.
   PubMed Web of Science ®Google Scholar
• Peng, L., R. Linghu, D. Chen, J. Yang, X. Kou, X. Z. Wang, Y. Hu, Y. Z. Jiang, and J. Yang. 2017. Inhibition of glutathione metabolism attenuates esophageal cancer progression. Exp. Mol. Med. 49 (4):e318. doi:10.1038/emm.2017.15.
   PubMedGoogle Scholar
• Pereira, D. L., A. C. Dos Santos Ferreira, G. P. de Faria, and J. K. Kwee. 2015. Autophagy interplays with apoptosis and cell cycle regulation in the growth inhibiting effect of Trisenox in HEP-2, a laryngeal squamous cancer. Pathol. Oncol. Res. 21 (1):103–11. doi:10.1007/s12253-014-9794-6.
   PubMed Web of Science ®Google Scholar
• Pereira, I. C., I. F. Mascarenhas, V. C. Capetini, P. M. P. Ferreira, M. M. Rogero, and F. L. Torres-Leal. 2022. Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer. Crit. Rev. Oncol. Hematol. 179:103796. doi:10.1016/j.critrevonc.2022.103796.
   PubMed Web of Science ®Google Scholar
• Perillo, B., M. Di Donato, A. Pezone, E. Di Zazzo, P. Giovannelli, G. Galasso, G. Castoria, and A. Migliaccio. 2020. ROS in cancer therapy: The bright side of the moon. Exp. Mol. Med. 52 (2):192–203. doi:10.1038/s12276-020-0384-2.
   PubMed Web of Science ®Google Scholar
• Qin, Z., S. Ou, L. Xu, K. Sorensen, Y. Zhang, D. P. Hu, Z. Yang, W. Y. Hu, F. Chen, and G. S. Prins. 2021. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH–Deficient prostate cancer cells. Chem. Biol. Drug. Des. 97 (5):1059–78. doi:10.1111/cbdd.13826.
   PubMed Web of Science ®Google Scholar
• Révész, L., M. R. Edgren, and A. A. Wainson. 1994. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 29:403–06. doi:10.1016/0360-3016(94)90298-4.
   PubMed Web of Science ®Google Scholar
• Robinson, N. B., K. Krieger, F. M. Khan, W. Huffman, M. Chang, A. Naik, R. Yongle, I. Hameed, K. Krieger, L. N. Girardi, et al. 2019. The current state of animal models in research: A review. Int. J. Surg. 72:9–13. doi:10.1016/j.ijsu.2019.10.015.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Gómez, I., J. Carmona-Cortés, R. Wangensteen, P. Vargas-Tendero, I. Banegas, A. Quesada, A. M. García-Lora, and F. Vargas. 2014. The pro-oxidant buthionine sulfoximine (BSO) reduces tumor growth of implanted Lewis lung carcinoma in mice associated with increased protein carbonyl, tubulin abundance, and aminopeptidase activity. Tumour Biol. 35 (8):7799–805. doi:10.1007/s13277-014-2046-2.
   PubMedGoogle Scholar
• Romero-Canelón, I., M. Mos, and P. J. Sadler. 2015. Enhancement of selectivity of an organometallic anticancer agent by redox modulation. J. Med. Chem. 58 (19):7874–80. doi:10.1021/acs.jmedchem.5b00655.
   PubMed Web of Science ®Google Scholar
• Saikawa, Y., T. Kubota, T. H. Kuo, T. Furukawa, H. Tanino, M. Watanabe, K. Ishibiki, and M. Kitajima. 1993. Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine. Jpn. J. Cancer Res. 84 (7):787–93. doi:10.1111/j.1349-7006.1993.tb02045.x.
   PubMedGoogle Scholar
• Sbardelotto, A. B., F. W. A. Barros, B. M. Soares, B. C. Cavalcanti, R. W. R. Sousa, M. P. Costa, O. D. L. Pessoa, C. Pessoa, and P. M. P. Ferreira. 2021. Cellular and biochemical antileukemic mechanisms of the meroterpenoid oncocalyxone a. J. Toxicol. Environ. Health A 84 (3):95–111. doi:10.1080/15287394.2020.1835763.
   PubMed Web of Science ®Google Scholar
• Schneider, E., H. Yamazaki, B. K. Sinha, and K. H. Cowan. 1995. Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation. Br. J. Cancer 71 (4):738–43. doi:10.1038/bjc.1995.144.
   PubMed Web of Science ®Google Scholar
• Siemann, D., and K. Beyers. 1993. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Br. J. Cancer 68 (6):1071–79. doi:10.1038/bjc.1993.484.
   PubMed Web of Science ®Google Scholar
• Skapek, S. X., O. M. Colvin, O. W. Griffith, G. B. Elion, D. D. Bigner, and H. S. Friedman. 1988. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res. 48 (10):2764–67.
   PubMed Web of Science ®Google Scholar
• Sobhakumari, A., L. Love-Homan, E. V. Fletcher, S. M. Martin, A. D. Parsons, D. R. Spitz, C. M. Knudson, and A. L. Simons. 2012. Simons, Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS One 7 (10):e48175. doi:10.1371/journal.pone.0048175.
   PubMed Web of Science ®Google Scholar
• Son, M. H., K. W. Kang, C. H. Lee, and S. G. Kim. 2001. Potentiation of cadmium-induced cytotoxicity by sulfur amino acid deprivation through activation of extracellular signal-regulated kinase1/2 (ERK1/2) in conjunction with p38 kinase or c-jun N-terminal kinase (JNK). Complete inhibition of the potentiated toxicity by U0126 an ERK1/2 and p38 kinase inhibitor. Biochem. Pharmacol. 62 (10):1379–90. doi:10.1016/s0006-2952(01)00780-8.
   PubMed Web of Science ®Google Scholar
• Sreedharan, S., G. Zouganelis, S. J. Drake, G. Tripathi, and A. Kermanizadeh. 2023. Nanomaterial-induced toxicity in pathophysiological models representative of individuals with pre-existing medical conditions. J. Toxicol. Environ. Health B 26 (1):1–27. doi:10.1080/10937404.2022.2153456.
   PubMedGoogle Scholar
• Sung, H., J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3):209–49. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Sun, G., W. Hu, J. Zhang, and S. Jing. 2012. Study on effect of BSO on esophageal cancer cell line TE-1. Chin. -Ger. J. Clin. Oncol 11 (11):638–43. doi:10.1007/s10330-012-1082-x.
   Google Scholar
• Su, L. J., J. H. Zhang, H. Gomez, R. Murugan, X. Hong, D. Xu, F. Jiang, and Z. Y. Peng. 2019. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid. Med. Cell Longev. 2019:5080843. doi:10.1155/2019/5080843.
   PubMed Web of Science ®Google Scholar
• Vahrmeijer, A. L., J. H. van Dierendonck, J. Schutrups, C. J. van de Velde, and G. J. Mulder. 1999. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: Enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery. Cancer Chemother. Pharmacol. 44 (2):111–16. doi:10.1007/s002800050954.
   PubMed Web of Science ®Google Scholar
• Vesterinen, H. M., E. S. Sena, K. J. Egan, T. C. Hirst, L. Churolov, G. L. Currie, A. Antonic, D. W. Howells, and M. R. Macleod. 2014. Meta-analysis of data from animal studies: A practical guide. J. Neurosci. Meth. 221:92–102. doi:10.1016/j.jneumeth.2013.09.010.
   PubMed Web of Science ®Google Scholar
• Villablanca, J. G., S. L. Volchenboum, H. Cho, M. H. Kang, S. L. Cohn, C. P. Anderson, A. Marachelian, S. Groshen, D. Tsao-Wei, K. K. Matthay, et al. 2016. A phase I new approaches to neuroblastoma therapy study of buthionine sulfoximine and melphalan with autologous stem cells for recurrent/refractory high‐risk neuroblastoma. Pediatr. Blood Cancer. 63(8):1349–56. doi:10.1002/pbc.25994.
   PubMed Web of Science ®Google Scholar
• Vries, R. B. M., C. R. Hooijmans, M. W. Langendam, J. Van Luijk, M. Leenaars, M. Ritskes-Hoitinga, and K. E. Wever. 2015. A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. Evid-Based Preclin. Med 2 (1):1–9. doi:10.1002/ebm2.7.
   Google Scholar
• Wang, Y., H. Lu, D. Wang, S. Li, K. Sun, X. Wan, E. W. Taylor, and J. Zhang. 2012. Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase. Toxicol. App. l Pharmacol. 265 (3):342–50. doi:10.1016/j.taap.2012.09.001.
   PubMed Web of Science ®Google Scholar
• Wang, C., J. Wang, X. Pan, S. Yu, M. Chen, Y. Gao, Z. Song, and M. Qiao. 2023. Reversing ferroptosis resistance by MOFs through regulation intracellular redox homeostasis. Asian J. Pharm. Sci. 18 (1):100770. doi:10.1016/j.ajps.2022.11.004.
   PubMed Web of Science ®Google Scholar
• Watanabe, T., H. Sagisaka, S. Arakawa, Y. Shibaya, M. Watanabe, I. Igarashi, K. Tanaka, S. Totsuka, W. Takasaki, and S. Manabe. 2003. A novel model of continuous depletion of glutathione in mice treated with L-buthionine (S,R)-sulfoximine. J. Toxicol. Sci. 28 (5):455–69. doi:10.2131/jts.28.455.
   PubMedGoogle Scholar
• Wei, Y., Z. Wang, J. Yang, R. Xu, H. Deng, S. Ma, T. Fang, J. Zhang, and Q. Shen. 2022. Reactive oxygen species/photothermal therapy dual-triggered biomimetic gold nanocages nanoplatform for combination cancer therapy via ferroptosis and tumor-associated macrophage repolarization mechanism. J. Colloid Interface Sci. 606:1950–65. doi:10.1016/j.jcis.2021.09.160.
   PubMed Web of Science ®Google Scholar
• Whitt, J. D., A. B. Keeton, B. D. Gary, L. A. Sklar, K. Sodani, Z. S. Chen, and G. A. Piazza. 2016. Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J. Biomed. Res. 30 (2):120–33. doi:10.7555/JBR.30.20150108.
   PubMedGoogle Scholar
• Wilding, J. L., and W. F. Bodmer. 2014. Cancer cell lines for drug discovery and development. Cancer Res. 74 (9):2377–84. doi:10.1158/0008-5472.
   PubMed Web of Science ®Google Scholar
• Wu, C., M. Q. Gong, B. Y. Liu, R. X. Zhuo, and S. X. Cheng. 2017. Co-delivery of multiple drug resistance inhibitors by polymer/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance. Colloids. Surf. B Biointerfaces. 149:250–59. doi:10.1016/j.colsurfb.2016.10.029.
   PubMed Web of Science ®Google Scholar
• Yoo, J., S. Jang, C. Park, D. Lee, S. Kwon, and H. Koo. 2020. Lowering glutathione level by buthionine sulfoximine enhances in vivo photodynamic therapy using chlorin e6-loaded nanoparticles. Dyes. Pigment 176:108207. doi:10.1016/j.dyepig.2020.108207.
   Web of Science ®Google Scholar
• Yu, M., S. K. Selvaraj, M. M. Liang-Chu, S. Aghajani, M. Busse, J. Yuan, G. Lee, F. Peale, C. Klijn, R. Bourgon, et al. 2015. A resource for cell line authentication, annotation and quality control. Nature 520 (7547):307–11. doi:10.1038/nature14397.
   PubMed Web of Science ®Google Scholar
• Zhang, R. X., H. L. Wong, H. Y. Xue, J. Y. Eoh, and X. Y. Wu. 2016. Nanomedicine of synergistic drug combinations for cancer therapy - strategies and perspectives. J. Control Rele. 240:489–503. doi:10.1016/j.jconrel.2016.06.012.
   PubMed Web of Science ®Google Scholar
• Zhao, Y., S. Tanaka, B. Yuan, K. Sugiyama, K. Onda, A. Kiyomi, N. Takagi, M. Sugiura, and T. Hirano. 2019. Arsenic disulfide combined with l-buthionine-(s, r)-sulfoximine induces synergistic antitumor effects in two-dimensional and three-dimensional models of mcf-7 breast carcinoma cells. Am. J. Chin. Med. 47 (05):1149–70. doi:10.1142/S0192415X19500599.
   PubMedGoogle Scholar
• Zhong, H., P. Y. Huang, P. Yan, P. L. Chen, Q. Y. Shi, Z. A. Zhao, J. X. Chen, X. Shu, P. Wang, B. Yang, et al. 2021. Versatile nanodrugs containing glutathione and heme oxygenase 1 inhibitors enable suppression of antioxidant defense system in a two-pronged manner for enhanced photodynamic therapy. Adv. Health. Mater. 10(19):e2100770. doi:10.1002/adhm.202100770.
   PubMed Web of Science ®Google Scholar